Cargando…

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers to reach the target concentration. CYP3A5 exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Gelder, Teun, Meziyerh, Soufian, Swen, Jesse J., de Vries, Aiko P. J., Moes, Dirk Jan A. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411304/ https://www.ncbi.nlm.nih.gov/pubmed/32848756 http://dx.doi.org/10.3389/fphar.2020.01142

Ejemplares similares

Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism
por: Klomp, Sylvia D., et al.
Publicado: (2022)

Commentary: The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: Thölking, Gerold, et al.
Publicado: (2021)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics
por: Meziyerh, Soufian, et al.
Publicado: (2020)

Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
por: Zhai, Qinglian, et al.
Publicado: (2022)

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation
por: Woillard, Jean-Baptiste, et al.
Publicado: (2017)

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients
por: Martial, Lisa C., et al.
Publicado: (2021)

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose
por: Andrews, Louise M., et al.
Publicado: (2017)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
por: de Jong, Laura M., et al.
Publicado: (2023)

Evaluation of limited-sampling strategies to calculate AUC((0–24)) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus
por: Galvez, Carla, et al.
Publicado: (2023)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
por: Yang, Yilei, et al.
Publicado: (2021)

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients
por: Pinon, Michele, et al.
Publicado: (2021)

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients
por: Moes, D. J. A. R, et al.
Publicado: (2015)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)

Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
por: Srinivas, Lekshmy, et al.
Publicado: (2021)

Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients
por: Zwart, Tom C., et al.
Publicado: (2022)

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients
por: Mendrinou, Effrosyni, et al.
Publicado: (2020)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients
por: Bunthof, Kim L. W., et al.
Publicado: (2021)

The Clinical Utility of Post-Transplant Monitoring of Donor-Specific Antibodies in Stable Renal Transplant Recipients: A Consensus Report With Guideline Statements for Clinical Practice
por: van den Broek, Dennis A. J., et al.
Publicado: (2023)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients
por: Andrews, L. M., et al.
Publicado: (2019)

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
por: Kagaya, Hideaki, et al.
Publicado: (2018)

Transplant Recipients Using Tacrolimus Had Higher Utilization of Healthcare Services Than Those Receiving Cyclosporine in Taiwan
por: Lin, Yi-Chang, et al.
Publicado: (2019)

Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients
por: Zhu, Huaijun, et al.
Publicado: (2022)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients
por: Tang, Jiang-Tao, et al.
Publicado: (2018)

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
por: Francke, Marith I., et al.
Publicado: (2020)

Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children
por: Gonçalves, Bronner P., et al.
Publicado: (2017)

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis
por: Kim, Jung Sun, et al.
Publicado: (2023)

Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients
por: Azam, Fahad, et al.
Publicado: (2022)

Genotype-guided tacrolimus dosing in African American kidney transplant recipients
por: Sanghavi, K., et al.
Publicado: (2015)

A new method to calculate intra‐patient variability in tacrolimus concentrations
por: van Gelder, Teun
Publicado: (2021)

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus
por: Pasternak, Amy L, et al.
Publicado: (2021)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors
por: Levens, Amar D., et al.
Publicado: (2023)

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
por: Manson, Lisanne E. N., et al.
Publicado: (2020)

Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
por: Lv, Binbin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v6b3nhn3rb3u970inl6opms9nf